Oncology Markets for Tyrokinse Kinase Inhibitors

Traditional cancer therapy has focused on removal or destruction of tumors cells by surgery, radiation and rather non-selective types of chemotherapy. Surgery and radiation are often effective with tumors which are localized and have not metastasized to multiple sites throughout the body. Intensive research and clinical trial activity have led to a number of targeted treatments, using novel pathways and signaling, that have achieved results representing a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. One promising area is a class of drugs known as tyrosine kinase inhibitors, which  phosphorylate specific amino acids on substrate enzymes, changes that subsequently alter signal transduction leading to downstream changes in cellular biology. This report examines and analyzes the three dozen therapeutic drugs that are defining the TKI oncology space.

What is the market share of approved TKI therapeutics?

• What is the global supply picture for targeted TKI therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic TKI coverage across all oncology indications?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive TKI picture for the major Oncology market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation TKI therapeutics?